Retatrutide vs Tirzepatide vs Semaglutide: What Is the Difference?

Peptide Library

Retatrutide, tirzepatide and semaglutide are distinct molecules. They share an interest in metabolic signalling, but differ in receptor activity, evidence and regulatory status. Understanding those differences is more useful than treating the names as interchangeable.

The receptor targets

Semaglutide activates GLP-1 receptors. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide activates GIP, GLP-1 and glucagon receptors. The terms single, dual and triple agonist refer to these target patterns. A higher number of targets is not a stand-alone ranking of safety, suitability or effectiveness. [4][1][6]

Approved medicines and investigation

Named semaglutide and tirzepatide medicines have approved indications in particular jurisdictions. Retatrutide remains investigational in Lilly’s September 2026 update. Approval of a named medicine does not automatically extend to a research-labelled vial, a different formulation or a combination preparation. Always separate the molecule being discussed from the actual product being offered. [5][3][6]

What a direct comparison can tell us

SURMOUNT-5 randomised 751 adults with obesity without type 2 diabetes to tirzepatide or semaglutide. At 72 weeks, mean body-weight change was −20.2% versus −13.7%, respectively. The study was open-label and used specific maximum tolerated treatment doses. It provides evidence for that head-to-head comparison in that population. It does not include retatrutide and cannot decide the best treatment for every individual. [7]

Why separate trial headlines can mislead

Different trials can enrol different people, run for different durations and handle treatment discontinuation differently. Comparing the largest percentage from one study with another study’s headline can create a misleading league table. Without a suitable direct comparison, conclusions about one compound being universally superior are not justified.

Safety and practical interpretation

The semaglutide and tirzepatide labels describe important adverse effects and contraindications. Retatrutide’s safety is still being evaluated. Treatment selection also depends on medical history, other medicines, the authorised indication and the actual product. This comparison explains research distinctions rather than recommending a switch or a combination. [2][4][6]

Frequently asked questions

Is retatrutide a semaglutide–tirzepatide blend?

No. It is a separate molecule with three receptor targets.

Does SURMOUNT-5 prove tirzepatide is best for everyone?

No. It answers a specific trial question in a defined population.

Can these compounds be substituted milligram for milligram?

No. A shared unit of mass does not establish equivalent biological activity or treatment.

Explore related articles

Sources

  1. DailyMed: current Mounjaro prescribing information
  2. SAHPRA: tirzepatide professional information — mechanism
  3. Aspen corporate announcement: SAHPRA weight-management indication, October 2025
  4. DailyMed: Wegovy prescribing information, June 2026
  5. Novo Nordisk South Africa: registered Wegovy presentations
  6. Lilly: retatrutide development and regulatory status, September 2026
  7. Aronne et al., 2025: SURMOUNT-5 head-to-head trial

Research checked: 11 October 2026. Educational information; not a diagnosis, prescription or dosing guide. Prepared for SkyCor with AI-assisted research and drafting; not independently medically reviewed. Approval information relates to the named products and jurisdictions, not every product carrying the same ingredient name.

Author